Prevention of recurrent esophageal variceal hemorrhage: Review and current recommendations

Journal of Clinical Gastroenterology

Volumn 41, Issue SUPPL. 3, 2007, Pages

  Kravetz, David ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Portal hypertension; Secondary prophylaxis of variceal rebleeding; Variceal rebleeding

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ISOSORBIDE MONONITRATE; NADOLOL; SUCRALFATE; VASODILATOR AGENT;

ASTHMA; BETA ADRENERGIC RECEPTOR BLOCKING; BRADYCARDIA; CONFERENCE PAPER; ENDOSCOPIC SCLEROTHERAPY; ESOPHAGUS VARICES; ESOPHAGUS VARICES BLEEDING; FATIGUE; HEART FAILURE; HUMAN; INSOMNIA; MORTALITY; OUTCOME ASSESSMENT; PORTAL HYPERTENSION; PORTOSYSTEMIC ANASTOMOSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENT DISEASE; SECONDARY PREVENTION; SEXUAL DYSFUNCTION; TREATMENT PLANNING;

ADRENERGIC BETA-ANTAGONISTS; COMBINED MODALITY THERAPY; ENDOSCOPY; ESOPHAGEAL AND GASTRIC VARICES; GASTROINTESTINAL HEMORRHAGE; HEMOSTATIC TECHNIQUES; HEMOSTATICS; HUMANS; HYPERTENSION, PORTAL; ISOSORBIDE DINITRATE; LIGATION; LIVER CIRRHOSIS; PORTACAVAL SHUNT, SURGICAL; PORTAL PRESSURE; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; PRACTICE GUIDELINES AS TOPIC; RECURRENCE; SCLEROTHERAPY; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 35848970036     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e318157f0a7     Document Type: Conference Paper

References (43)

1. D'Amico G, Morabito A, Pagliaro L, et al. Survival and prognostic indicators in compensated and decompensate cirrhosis. Dig Dis Sci. 1986;31:468-465.
2. Graham DY, Smith JL. The course of patients after variceal hemorrhage. Gastroenterology. 1981;80:800-809.
3. Pagliaro L, D'Amico G, Pasta L, et al. Portal hypertension in cirrhosis: natural history. In: Bosch J, Groszmann RJ, eds. Portal Hypertension. Pathophysiology and Treatment. Oxford: Blackwell; 1994:72-92.
4. Lebrec D, Stiegmann G. Prevention of recurrent variceal haemorrhage. Secondary Prophylaxis. Portal Hypertension. Proceedings of the Third Baveno International Consensus Workshop. Blackwell Science, 2001.
5. Burroughs AK, Cales P, Kravetz D, et al. Definition key events. Last attempts? In: Franchis RD, ed. Portal Hypertension IV. Proceedings of the Fourth Baveno International Consensus Workshop. Blackwell Publishing; 2006:11-39.
6. Endpoints Single Topic Conference. AASLD. Portal Hypertension and Variceal Bleeding unresolved issues. Atlanta, June, 4-6, 2007.
7. D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis. 1999;19:475-505.
8. Navasa M, Chesta J, Bosch J, et al. Reduction of portal pressure by isosorbide-5-mononitrate in patients with cirrhosis. Effects on splanchnic and systemic hemodynamics and liver function. Gastroenterology. 1989;96:1110-1118.
9. Gournay J, Masliha C, Martin T, et al. Isosorbide mononitrate and propanolol compared with proprandol alone for the prevention of variceal rebleeding. Hepatology. 2000;31:1239-1245.
10. Patti R, D'Amico G, Pasta L, et al. Isosorbide mononitrate with nadolol compared to nadolol alone for prevention of recurrent bleeding in cirrhosis. A double-blind placebo-controlled randomized trial. J Hepatol. 1999;30(suppl):81A.
11. Villanueva C, Balanzó J, Novella MT, et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med. 1996;334:1624-1629.
12. Talwalkar JA, Kamath PS. An evidence-based medicine approach to Beta-blocker therapy in patients with cirrhosis. Am J Med. 2004;116:759-766.
13. Bosch J, Garcia-Pagan JC. Prevention of variceal rebleeding. Lancet. 2003;361:952-954.
14. Groszmann RJ, Garcia-Tsao G, Bosch J. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med. 2005;353:2254-2261.
15. D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta- analytic review. Hepatology. 1995;22:332-354.
16. Bernard B, Lebrec D, Mathurin P, et al. Propranolol and sclerotherapy in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. J Hepatol. 1997;26:312-324.
17. de Franchis R, Primignani M. Endoscopic treatments for portal hypertension. Semin Liver Dis. 1999;19:439-455.
18. Laine L, el Newihi HM, Migikovsky B, et al. Endoscopic ligation compared with sclerotherapy for the treatment of bleeding esophageal varices. Ann Intern Med. 1993;119:1-7.
19. de Franchis R. Updating consensus in portal hypertension: report of the Baveno III consensus workshop on definitions, methodology and therapeutic strategies in portal hypertension. J Hepatol. 2000;33:846-852.
20. Jalan R, Hayes PC. UK guidelines on the management of variceal haemorrhage in cirrhotic patients. British Society of Gastroenterology. Gut. 2000;46(suppl 3-4):III1-III15.
21. Villanueva C, Minana J, Ortiz J, et al. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med. 2001;345:647-655.
22. Lo G-H, Chen W-C, Chen M-H, et al. Banding ligation versus nadolol and isosorbide mononitrate for the prevention of esophageal variceal rebleeding. Gastroenterology. 2002;123:728-734.
23. Patch D, Sabin CA, Goulis J, et al. A randomized, controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis. Gastroenterology. 2002;123:1013-1019.
24. Romero G, Kravetz D, Argonz J, et al. Comparative study between nadolol and 5-isosorbide mononitrate vs. endoscopic band ligation plus sclerotherapy in the prevention of variceal rebleeding in cirrhotic patients: a randomized controlled trial. Aliment Pharmacol Ther. 2006;24:601-611.
25. Dagher L, Patch D, Burroughs A. Drug treatment for bleeding oesophageal varices. Baillieres Best Pract Res Clin Gastroenterol. 2000;14:365-390.
26. Lo GH, Lai KH, Cheng JS, et al. Endoscopic variceal ligation plus nadolol and sucralfate compared with ligation alone for the prevention of variceal rebleeding: a prospective, randomized trial. Hepatology. 2000;32:461-465.
27. de la Peña J, Brullet E, Sanchez-Hernández E, et al. Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding: a multicenter trial. Hepatology. 2005;41:572-578.
28. Study Group Spanish Cooperative Variceal Rebleeding. Multicenter RCT comparing drug therapy+endoscopic band ligation in the prevention of rebleeding in patients with cirrhosis. Hepatology. 2006;202A:30.
29. Singh P, Pooran N, Indaram A, et al. Combined ligation and sclerotherapy versus ligation alone for secondary prophylaxis of esophageal variceal bleeding: a metaanalysis. Am J Gastroenterol. 2002;97:623-629.
30. Argonz J, Kravetz D, Suarez A, et al. Variceal Band Ligation and Variceal Band Ligation plus sclerotherapy in the prevention of recurrent variceal bleeding in cirrhotic patients. A randomized, prospective and controlled trial. Gastrointest Endosc. 2000;51:157-163.
31. Mela M, Thalheimer U, Burroughs A. Prevention of variceal rebleeding - approach to management. Medscape Gen Med. 2003;5:5-9.
32. Papatheodoridis GV, Goulis J, Leandro G, et al. Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding: a meta-analysis. Hepatology. 1999;30:612-622.
33. Escorsell AM, Banares R, Garcia-Pagan JC, et al. TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: a randomized controlled trial. Hepatology. 2002;35:385-392.
34. Jalan R, Forrest EH, Stanley AJ, et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology. 1997;26:1115-1122.
35. Sauer P, Hansmann J, Richter GM, et al. Endoscopic variceal ligation plus propranolol vs. transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. Endoscopy. 2002;34:690-697.
36. Pomier-Layrargues G, Villeneuve JP, Deschênes M, et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomized trial. Gut. 2001;48:390-396.
37. Gulberg V, Schapke M, Geingenberger G, et al. Transjugular intrahepatic portosystemic shunting is not superior to endoscopic variceal band ligation for prevention of variceal rebleeding in cirrhotic patients: a randomized, controlled trial. Scand J Gastroenterol. 2002;37:338-343.
38. Rosemurgy AS, Serafini FM, Zweibel BR, et al. Transjugular intrahepatic portosystemic shunt vs. small-diameter prosthetic H-graft portacaval shunt: extended follow-up of an expanded randomized prospective trial. J Gastrointest Surg. 2000;4:589-597.
39. Rosemurgy AS, Bloomston M, Zervos EE, et al. Transjugular intrahepatic portosystemic shunt versus H-graft portacaval shunt in the management of bleeding varices: a cost-benefit analysis. Surgery. 1997;122:794-799.
40. Rosemurgy AS, Goode SE, Zwiebel BR, et al. A prospective trial of transjugular intrahepatic portosystemic stent shunts versus smalldiameter prosthetic H-graft portacaval shunts in the treatment of bleeding varices. Ann Surg. 1996;224:378-384.
41. Henderson JM, Boyer TD, Kutner MH. Distal splenorenal shunt versus transjugular intrahepatic portal systematic shunt for variceal bleeding: a randomized trial. Gastroenterology. 2006;130:1643-1651.
42. Bureau C, Garcia-Pagan JC, Otal P, et al. Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology. 2004;126:469-475.
43. Bernard-Chabert B, Sauerbruch T, Lo GH. Definition key events. Last attempts? In: Franchis RD, ed. Portal Hypertension IV. Proceedings of the Fourth Baveno International Consensus Workshop. Blackwell Publishing; 2006:262-284.